Drug intelligence / Profile preview

CAN-001

Development stage: Unknown
Lead developer: Zelira Therapeutics
Modality: Small Molecules

Overview

**CAN-001** is a chemical drug initially developed by Zelira Therapeutics Ltd. for **chemotherapy-induced nausea and vomiting (CINV)**, with its global highest R&D status listed as Pending in the therapeutic area of Other Diseases. No specific mechanism of action, targets, or active indications are detailed in available data, and no ongoing clinical trials or further development updates are identified.[1]

Beyond the preview

Go deeper on CAN-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAN-001.

Explore the full profile